"Single-Domain Antibodies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An immunoglobulin fragment composed of one variable domain from an IMMUNOGLOBULIN HEAVY CHAIN or IMMUNOGLOBULIN LIGHT CHAIN.
| Descriptor ID |
D061905
|
| MeSH Number(s) |
D12.644.541.500.650.500.900 D12.776.124.486.485.680.650.500.900 D12.776.124.790.651.680.650.500.900 D12.776.377.715.548.680.650.500.897
|
| Concept/Terms |
VHH Immunoglobulin Fragments- VHH Immunoglobulin Fragments
- Fragments, VHH Immunoglobulin
- Immunoglobulin Fragments, VHH
- Nanobodies
- VHH Fragments
- Fragments, VHH
VNAR Immunoglobulin Fragments- VNAR Immunoglobulin Fragments
- Fragments, VNAR Immunoglobulin
- Immunoglobulin Fragments, VNAR
- VNAR Fragments
- Fragments, VNAR
|
Below are MeSH descriptors whose meaning is more general than "Single-Domain Antibodies".
Below are MeSH descriptors whose meaning is more specific than "Single-Domain Antibodies".
This graph shows the total number of publications written about "Single-Domain Antibodies" by people in this website by year, and whether "Single-Domain Antibodies" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Single-Domain Antibodies" by people in Profiles.
-
Immune Thrombotic Thrombocytopenic Purpura: A Review. JAMA. 2025 08 12; 334(6):517-529.
-
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries. MAbs. 2022 Jan-Dec; 14(1):2002236.
-
Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021 01; 9(1):21-32.
-
Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. Am J Hematol. 2020 04; 95(4):E76-E77.
-
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016 01; 60(1):6-13.
-
Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis. Infect Immun. 2015 Feb; 83(2):502-13.